Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has provided an update.
On December 15, 2025, OKYO Pharma Limited announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 24,551 of the company’s ordinary shares on NASDAQ, increasing Cerrone’s total holding to 10,516,297 shares. This acquisition highlights the confidence in OKYO’s ongoing development of urcosimod, a promising treatment for neuropathic corneal pain and dry eye disease, which has shown significant results in Phase 2 trials, potentially enhancing the company’s market position in ophthalmology.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.
OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is engaged in the discovery and development of novel molecules, with its ordinary shares listed on the NASDAQ Capital Market.
Average Trading Volume: 157,381
Technical Sentiment Signal: Buy
Current Market Cap: $77.48M
Find detailed analytics on OKYO stock on TipRanks’ Stock Analysis page.